TransMedics Group Inc vs United Microelectronics Corp — how do they compare? TransMedics Group Inc trades at $87.08 (market cap $3.10B), while United Microelectronics Corp trades at $19.4 (market cap $47.81B). The key difference: United Microelectronics Corp is far larger — about 15.4× TransMedics Group Inc's market cap, and United Microelectronics Corp pays a 2.12% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| TMDX | UMC | |
|---|---|---|
Market Cap | $3.10B | $47.81B |
Sector | Technology | Technology |
52-Week High | $150.42 | $28.02 |
52-Week Low | $61.99 | $6.58 |
Enterprise Value | $3.49B | $44.93B |
Dividend Yield | — | 2.12% |
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
UMC trades at $19.50, up 3.78% today, with neutral technical signals and strong fundamental performance. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.54 significantly exceeding the $0.16 expectation. Recent announcements include fab expansions in Singapore and Taiwan to meet AI-driven demand, supported by growing silicon photonics production. Valuation metrics show a P/E of 18.55 and P/S of 6.02, with robust profitability margins including 32.75% net income margin.
Outlook remains positive with projected revenue growth to $250.7B in 2026 and net income rebound to $82.1B. Key risks include semiconductor cycle volatility and execution challenges from capacity expansion. Analyst consensus shows mixed sentiment with 26.7% buy ratings versus 20% sell recommendations, suggesting cautious optimism amid expansion initiatives.
Trailing returns across standard periods
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →